For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 0 | 0 | - | - |
| Research and development | 14,296 | 12,987 | 13,404 | 14,639 |
| General and administrative | 7,562 | 6,828 | 6,999 | 8,424 |
| Restructuring expenses | 0 | - | - | 2,063 |
| Total operating expenses | 21,858 | 19,815 | 20,403 | 25,126 |
| Loss from operations | -21,858 | -19,815 | -20,403 | -25,126 |
| Other income, net | 2,263 | 2,519 | 2,748 | 3,430 |
| Net (loss) income | -19,595 | -17,296 | -17,655 | -21,696 |
| Unrealized gain on marketable securities | 159 | - | - | - |
| Total other comprehensive gain | 159 | - | - | - |
| Comprehensive (loss) income | -19,436 | - | - | - |
| Earnings per share, basic | -0.31 | -0.28 | -0.28 | -0.35 |
| Earnings per share, diluted | -0.31 | -0.28 | -0.28 | -0.35 |
| Weighted-average common shares outstanding, basic | 62,597,000 | 62,544,000 | 62,479,000 | 62,409,000 |
| Weighted-average common shares outstanding, diluted | 62,597,000 | 62,544,000 | 62,479,000 | 62,409,000 |
Fulcrum Therapeutics, Inc. (FULC)
Fulcrum Therapeutics, Inc. (FULC)